Immunopathological reactions, endothelial dysfunction and pathological angiogenesis as independent mechanisms of maladaptive left ventricular remodeling in ischemic and nonischemic heart failure patients
DOI:
https://doi.org/10.14739/2310-1210.2021.2.211951Keywords:
heart failure, left ventricular remodeling, pathological angiogenesis, TNF-alpha, VEGF, endothelin-1Abstract
Regardless of the great progress in studying the heart failure (HF) pathophysiology, the question about involvement of immune cells activation, systemic inflammation, inflammatory cytokine dysregulation and endothelial dysfunction in maladaptive left ventricular (LV) remodeling in ischemic and nonischemic HF patients is still open to discussion.
The aim was to study the characteristics of immunopathological reactions (immunoinflammatory and autoimmune), endothelial dysfunction and pathologic angiogenesis in maladaptive LV remodeling in ischemic and nonischemic HF patients.
Materials and methods. A total of 20 healthy volunteers, 31 ischemic HF patients (group 1) and 43 nonischemic HF patients (group 2) were enrolled in the study. All the patients underwent coronarography, ventriculography, echocardigraphic examination. The main lymphocyte subset counts (flow cytometry), serum concentration of C-reactive protein (CRP), vascular endothelial growth factor A (VEGF), TNFα, endothelin-1 (enzyme-linked immunosorbent assay (ELISA)), autoantibodies to myocardium and vessels were detected.
Results. Regardless of the HF etiology, all the examined patients demonstrated echocardiographic features of maladaptive LV remodeling and severe intracardiac hemodynamic disorders that was associated with immune system activation, namely increased total and subset lymphocyte counts, chronic systemic inflammation (CRP), autoimmune process with an increase in autoantibodies to myocardium and vessels, and endothelial dysfunction (increased endothelin-1 and VEGF). Under-expression of TNF-α combined with over-expression of VEGF seemed to indicate pathological angiogenesis in ischemic and nonischemic HF patients
Conclusions. Significantly increased VEGF levels in heart failure patients can be considered as additional integral key marker of immune inflammation, endothelial dysfunction and pathological angiogenesis and may indicate maladaptive cardiac remodeling in severe heart failure.
References
Voronkov, L. H., Amosova, K. M., Dziak, H. V., Zharinov, O. Y., Kovalenko, V. M., Korkushko, O. V., Nesukai, O. H., Sychov, O. S., Rudyk, Yu. S., & Parkhomenko, O. M. (2017). Rekomendatsii Asotsiatsii kardiolohiv Ukrainy z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti (2017) [Guidelines of the Ukrainian Association of Cardiology for the Diagnosis and Treatment of Chronic Heart Failure (2017)]. Sertseva nedostatnist ta komorbidni stany, (1, dodatok 1), 1-66. [in Ukranian].
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J., Coats, A., Falk, V., González-Juanatey, J. R., Harjola, V. P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G., Ruilope, L. M., Ruschitzka, F., Rutten, F. H., … ESC Scientific Document Group. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37(27), 2129-2200. https://doi.org/10.1093/eurheartj/ehw128
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., Deaton, C., Graham, I., Hall, M. S., Hobbs, F., Løchen, M. L., Löllgen, H., Marques-Vidal, P., Perk, J., Prescott, E., Redon, J., Richter, D. J., … ESC Scientific Document Group. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 37(29), 2315-2381. https://doi.org/10.1093/eurheartj/ehw106
Konstam, M. A., Kramer, D. G., Patel, A. R., Maron, M. S., & Udelson, J. E. (2011). Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC: Cardiovascular Imaging, 4(1), 98-108. https://doi.org/10.1016/j.jcmg.2010.10.008
Frieler, R. A., & Mortensen, R. M. (2015). Immune Cell and Other Noncardiomyocyte Regulation of Cardiac Hypertrophy and Remodeling. Circulation, 131(11), 1019-1030. https://doi.org/10.1161/CIRCULATIONAHA.114.008788
King, M., Kingery, J., & Casey, B. (2012). Diagnosis and evaluation of heart failure. American Family Physician, 85(12), 1161-1168.
Heusch, G., Libby, P., Gersh, B., Yellon, D., Böhm, M., Lopaschuk, G., & Opie, L. (2014). Cardiovascular remodelling in coronary artery disease and heart failure. The Lancet, 383(9932), 1933-1943. https://doi.org/10.1016/S0140-6736(14)60107-0
Hilfiker-Kleiner, D., Landmesser, U., & Drexler, H. (2006). Molecular Mechanisms in Heart Failure. Journal of the American College of Cardiology, 48(9. Suppl. A), A56-A66. https://doi.org/10.1016/j.jacc.2006.07.007
da Lus, P. L., Libby, P., Laurindo, F. R. M., & Chagas, A. C. P. (2018). Endothelium and Cardiovascular Diseases. Vascular Biology and Clinical Syndromes. Academic Press.
Premer, C., Kanelidis, A. J., Hare, J. M., & Schulman, I. H. (2019). Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 3(1), 1-13. https://doi.org/10.1016/j.mayocpiqo.2018.12.006
Azevedo, P. S., Polegato, B. F., Minicucci, M. F., Paiva, S. A., & Zornoff, L. A. (2016). Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment. Arquivos Brasileiros de Cardiologia, 106(1), 62-69. https://doi.org/10.5935/abc.20160005
Evora, P. R., Nather, J., Tubino, P. V., Albuquerque, A. A., Celotto, A. C., & Rodrigues, A. J. (2013). Curbing Inflammation in the Ischemic Heart Disease. International Journal of Inflammation, 2013, Article 183061. https://doi.org/10.1155/2013/183061
Zhang, Y., Bauersachs, J., & Langer, H. F. (2017). Immune mechanisms in heart failure. European Journal of Heart Failure, 19(11), 1379-1389. https://doi.org/10.1002/ejhf.942
Ambrosova, T. N. (2013). Rol' tsitokinovoi sistemy v formirovanii khronicheskoi serdechnoi nedostatochnosti [Role of cytokine system on the chronic heart failure]. Eksperymentalna i klinichna medytsyna, (4), 61-67. [in Russian].
Heba, G., Krzemiński, T., Porc, M., Grzyb, J., & Dembińska-Kieć, A. (2001). Relation between expression of TNF alpha, iNOS, VEGF mRNA and development of heart failure after experimental myocardial infarction in rats. Journal of Physiology and Pharmacology, 52(1), 39-52.
Gavrilenko, T. I., Ryzhkova, N. A., & Parkhomenko, A. N. (2011). Sosudistyi endotelial'nyi faktor rosta v klinike vnutrennikh zabolevanii i ego patogeneticheskoe znachenie [Vascular endothelial growth factor in the clinic of internal diseases and its pathogenetic value]. Ukrainskyi kardiolohichnyi zhurnal, (4), 87-95. [in Russian].
Mangіliova, T. A. (2012). Sistema sosudistogo endotelial'nogo faktora rosta i arterial'naya gipertenziya [Vascular endothelial growth factor system and arterial hypertension]. Sertse i sudyny, (4), 107-115. [in Russian].
Libby, P. (2012). Inflammation in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(9), 2045-2051. https://doi.org/10.1161/ATVBAHA.108.179705
Hofmann, U., & Frantz, S. (2015). Role of Lymphocytes in Myocardial Injury, Healing, and Remodeling After Myocardial Infarction. Circulation Research, 116(2), 354-367. https://doi.org/10.1161/CIRCRESAHA.116.304072
Zhao, T., Zhao, W., Chen, Y., Liu, L., Ahokas, R. A., & Sun, Y. (2013). Differential expression of vascular endothelial growth factor isoforms and receptor subtypes in the infarcted heart. International Journal of Cardiology, 167(6), 2638-2645. https://doi.org/10.1016/j.ijcard.2012.06.127
Huusko, J., Merentie, M., Dijkstra, M. H., Ryhänen, M. M., Karvinen, H., Rissanen, T. T., Vanwildemeersch, M., Hedman, M., Lipponen, J., Heinonen, S. E., Eriksson, U., Shibuya, M., & Ylä-Herttuala, S. (2010). The effects of VEGF-R1 and VEGF-R2 ligands on angiogenic responses and left ventricular function in mice. Cardiovascular Research, 86(1), 122-130. https://doi.org/10.1093/cvr/cvp382
Ramji, D. P., & Davies, T. S. (2015). Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine & Growth Factor Reviews, 26(6), 673-685. https://doi.org/10.1016/j.cytogfr.2015.04.003
Libby, P., Bornfeldt, K. E., & Tall, A. R. (2016). Atherosclerosis: Successes, Surprises, and Future Challenges. Circulation Research, 118(4), 531-534. https://doi.org/10.1161/CIRCRESAHA.116.308334
Dati, F., & Metzmann, E. (2007). Belki. Laboratornye testy i klinicheskoe primenenie [Proteins. Laboratory Testing and Clinical Use]. Labora. [in Russian].
Kay, M. (2013). Physiologic Autoantibody and Immunoglobulin Interventions During Aging. Current Aging Science, 6(1), 56-62. https://doi.org/10.2174/1874609811306010008
Yakobysiak, M. (2004). Imunolohiia [Immunology]. Nova knyha. [in Ukranian].
Alem, M. M. (2019). Endothelial Dysfunction in Chronic Heart Failure: Assessment, Findings, Significance, and Potential Therapeutic Targets. International Journal of Molecular Sciences, 20(13), Article 3198. https://doi.org/10.3390/ijms20133198
Zheng, W., Seftor, E. A., Meininger, C. J., Hendrix, M. J., & Tomanek, R. J. (2001). Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGF-β. American Journal of Physiology. Heart and Circulatory Physiology, 280(2), H909-H917. https://doi.org/10.1152/ajpheart.2001.280.2.H909
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)